Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Lilly’s tirzepatide wins FDA approval for type 2 diabetes

By Brian Buntz | May 13, 2022

Eli LillyFDA has approved Mounjaro (tirzepatide), the first glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) for treating adults with type 2 diabetes.

Developed by Eli Lilly and Co., tirzepatide could quickly become a mega-blockbuster. Annual sales of the drug could approach $14 billion by 2030, according to Mizuho Securities.

To win approval, Lilly provided data from the Phase 3 SURPASS clinical studies showing that it supported superior A1C reductions than all comparators, including insulin glargine and insulin degludec. The SURPASS trials also pitted tirzepatide against metformin, SGLT2 inhibitors and sulfonylureas.

The drug could emerge as an important therapy for diabetes, FDA noted in a press release. “Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of Mounjaro is an important advance in the treatment of type 2 diabetes,” noted Dr. Patrick Archdeacon, associate director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, in a news release.

The drug also has the side effect of weight loss, although it is not indicated for obesity. Volunteers in the SURPASS trials lost an average of 12 and 25 lb., depending on dose level.

In the SURMOUNT-1 study, the drug yielded up to 22.5% weight loss in overweight or obese adults.

Lilly will market the drug in an auto-injector pin with a hidden needle. It will be available in six doses ranging from 2.5 to 15 mg.

LLY shares were mostly flat, holding steady at $291.63.

Lilly is also pursuing commercialization of tirzepatide in Europe, Japan and other regions.

The company is investigating tirzepatide for potential indications including heart failure, obesity and non-alcoholic steatohepatitis.


Filed Under: Metabolic disease/endicrinology
Tagged With: Eli Lilly and Co., GIP, GLP-1, Mounjaro, SURMOUNT, Tirzepatide
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Eli Lilly
Lilly’s tirzepatide gives Novo Nordisk’s semaglutide a run for the money in Phase 3 trial
Novo Nordisk
Novo Nordisk wins FDA approval for higher-dose Ozempic for adults with type 2 diabetes
Pfizer
Pfizer accuses former employees of trade secret theft
World Diabetes day (1)
7 diabetes treatment innovations to look out for on World Diabetes Day

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50